Elekta (STO:EKTA B) said today it won CE Mark approval in the European Union for its Elekta Unity magnetic resonance radiation therapy system.
The Stockholm-based company touted that its Unity system allows clinicians to deliver radiation doses while simultaneously visualizing the tumor and surrounding tissue through MR imaging. The system also features integrated advanced tools that allow the operator to adapt treatment based on anatomical information.
“Unity is a tremendous innovation in patient care, one that enables a scan-plan-treat approach to developing tailored regimens that should yield substantive clinical benefits. I am thrilled that our vision of personalized radiation therapy is becoming a clinical reality,” high-field MR-linac concept inventor Bas Raaymakers of the University Medical Center Utrecht said in a press release.
“Receiving CE mark for Unity is a big achievement in revolutionizing the field of radiation therapy and a real watershed moment for treating cancer. The change that MR/RT will bring in cancer therapy is paramount in advancing patient treatment. I’m thankful to the MR-linac Consortium members, Philips and our dedicated employees for helping us reach this important day,” CEO & prez Richard Hausmann said in a prepared statement.
In January, Elekta said it inked a collaborative sales deal with IBM‘s (NYSE:IBM) Watson Health through which Elekta will offer IBM’s Watson for Oncology with its cancer care solutions.
